The Lancet DECEMBER 08, 2011

CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION)

William T. Abraham, Philip B. Adamson, Robert C. Bourge, Maria M. Aaron, Peter B. Costanzo, Lynne W. Stevenson, et al.

Bottom Line

The CHAMPION trial demonstrated that hemodynamic management guided by remote, wireless pulmonary artery pressure monitoring significantly reduces heart failure-related hospitalizations in patients with symptomatic chronic heart failure.

Key Findings

1. The treatment group experienced a 37% reduction in heart failure-related hospitalization rates compared to the control group during the randomized follow-up period (0.32 vs. 0.44 events per patient per 6 months, p=0.0002).

2. Hemodynamic monitoring facilitated more frequent medication adjustments in the treatment group, enabling clinicians to proactively intervene before clinical decompensation occurred.

3. The reduction in heart failure hospitalizations was observed to be durable, and the benefit persisted across both patients with reduced and preserved left ventricular ejection fraction.

4. The device was associated with a favorable safety profile, with high rates of freedom from device- or system-related complications through 6 months of follow-up.

Study Design

Design

RCT

Single-Blind

Sample

550

Patients

Duration

15 mo

Median

Setting

Multicenter, US

Population Patients with New York Heart Association (NYHA) functional class III heart failure who had at least one heart failure hospitalization in the previous 12 months.

Intervention Implantation of a wireless pulmonary artery pressure sensor and management of heart failure guided by daily hemodynamic readings.

Comparator Implantation of the wireless pulmonary artery pressure sensor without the availability of hemodynamic data for the treating physician (standard of care).

Outcome Rate of heart failure-related hospitalizations within 6 months of randomization.

Study Limitations

• The study was single-blinded, potentially introducing detection or management bias despite the objective nature of the primary endpoint.

• The initial cohort was limited to New York Heart Association (NYHA) class III heart failure patients, which may restrict the generalizability of these findings to other heart failure classifications.

• The reliance on open-label follow-up after the randomized period may complicate the assessment of long-term comparative efficacy.

• The trial was conducted primarily at US centers, which might not reflect the variability in clinical practice or healthcare systems in other regions.

Clinical Significance

The CHAMPION trial established pulmonary artery pressure monitoring as a viable paradigm for the management of chronic heart failure. By transitioning from reactive care to proactive, hemodynamically-guided management, clinicians can mitigate the high morbidity associated with frequent hospitalizations, particularly in symptomatic patients who remain refractory despite adherence to conventional guideline-directed medical therapy.

Historical Context

Prior to the development and evaluation of the CardioMEMS sensor, heart failure management relied primarily on symptomatic assessment, weight monitoring, and episodic clinical evaluations. The CHAMPION trial marked a major innovation in digital health and implantable monitoring, validating that objective, real-time hemodynamic data could improve clinical outcomes beyond standard care, eventually leading to FDA approval for the device in patients with NYHA class III heart failure.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the physiological rationale for monitoring pulmonary artery pressures (PAP) rather than relying on daily weight measurements and physical exams for patients with NYHA Class III heart failure?

Key Response

Hemodynamic congestion (rising PAP) typically precedes clinical congestion (weight gain, peripheral edema, and dyspnea) by days or even weeks. The CHAMPION trial leverages this by allowing clinicians to adjust diuretics and vasodilators during the asymptomatic phase, preventing the escalation to a symptomatic crisis requiring hospitalization.

Resident

In the context of the CHAMPION trial, which specific patient population showed the most significant benefit from the CardioMEMS device, and how does this influence your selection process in the clinic?

Key Response

The trial enrolled NYHA Class III patients with at least one heart failure hospitalization in the previous 12 months. The benefit was consistent across both HFrEF and HFpEF phenotypes. Therefore, the device is most indicated for 'frequent flyers'—patients who remain symptomatic and unstable despite guideline-directed medical therapy (GDMT).

Fellow

Analyze the impact of pulmonary artery pressure-guided management on the use of neurohormonal antagonists and diuretics in the CHAMPION trial. Did the intervention group's outcomes stem solely from diuretic titration?

Key Response

While diuretic adjustments were the most frequent intervention (addressing volume), the CHAMPION data showed that clinicians also increased GDMT (ACE inhibitors/ARBs and beta-blockers) more frequently in the treatment group. This suggests that stable pressures provided clinicians with the confidence to optimize life-prolonging therapies that might otherwise have been withheld due to fear of hypotension or renal instability.

Attending

The CHAMPION trial demonstrated a 33% reduction in heart failure hospitalizations at 6 months. How does the implementation of this technology necessitate a paradigm shift in our multidisciplinary heart failure clinics?

Key Response

Successful integration requires moving from a reactive, clinic-visit-based model to a proactive, data-driven remote monitoring model. It requires dedicated nursing or advanced practice provider (APP) time to review daily uploads and standardized protocols for medication adjustment, as the device's efficacy is entirely dependent on the clinician's response to the transmitted data.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The CHAMPION trial employed a single-blind design where the control group received the implant but their data was not visible to their physicians. What are the ethical and methodological implications of this 'sham-like' control in medical device trials?

Key Response

The design was crucial to isolate the effect of the information (data-guided management) rather than the placebo effect of the procedure or the presence of the device. Ethically, this requires a high burden of proof that the potential benefit outweighs the risk of an invasive procedure for the control group. Methodologically, it ensures that the reduction in hospitalizations is truly due to better management decisions.

Journal Editor

What specific threats to internal validity should a reviewer flag when evaluating the CHAMPION trial's long-term extension data, particularly regarding 'crossover' or changes in the control group's management after the primary endpoint was met?

Key Response

Once the primary results were known, the control group was often given access to their data (crossover). This makes long-term comparative efficacy and mortality analysis difficult, as the 'pure' control group is lost. A reviewer would also look for evidence of 'monitoring fatigue'—whether the frequency of data review and physician responsiveness declined over time, potentially attenuating the treatment effect.

Guideline Committee

Given that the CHAMPION trial and subsequent meta-analyses show a reduction in hospitalizations but not a definitive reduction in all-cause mortality, how should the strength of recommendation for PAP monitoring be structured in the next guideline update?

Key Response

Currently, the 2022 AHA/ACC/HFSA guidelines provide a Class 2b recommendation (Level of Evidence: B-R) for PAP monitoring in NYHA Class III patients with prior HF hospitalizations. To move to a Class 2a or Class 1 recommendation, the committee would likely require more robust evidence of mortality benefit or broader real-world data demonstrating consistent cost-effectiveness and efficacy across diverse healthcare systems.

Clinical Landscape

Noteworthy Related Trials

2008

COACH Trial

n = 1,023 · Eur Heart J

Tested

Multidisciplinary heart failure management program (basic vs intensive support)

Population

Patients hospitalized with heart failure

Comparator

Care as usual

Endpoint

Time to all-cause mortality or cardiovascular readmission

Key result: Neither intensive nor basic support programs improved the primary outcome compared to usual care in this broad heart failure population.

2010

ESC-HF Pilot Study

n = 4,992 · Eur J Heart Fail

Tested

Registry-based observation of standard heart failure care

Population

Patients with acute or chronic heart failure

Comparator

N/A (Observational)

Endpoint

12-month all-cause mortality

Key result: High rates of morbidity and mortality were observed, highlighting the ongoing clinical burden of heart failure despite established treatment guidelines.

2021

GUIDE-HF Trial

n = 1,000 · Lancet

Tested

Hemodynamic-guided management using CardioMEMS PA pressure sensor

Population

NYHA class II-IV heart failure patients with elevated NT-proBNP or prior hospitalization

Comparator

Standard of care without PA pressure guidance

Endpoint

Composite of all-cause mortality, heart failure hospitalization, and urgent heart failure visits

Key result: The primary endpoint showed a trend toward reduction that was not statistically significant in the overall cohort, though it suggested benefit in specific high-risk subgroups.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis